Exelixis Continues On

Shares of Exelixis (NASDAQ: EXEL  ) got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of the year -- investors were clearly hoping that the drug would work so well that the trial would be stopped early.

While the trial could still prove successful on the final look at the data, some of the stock price decline is warranted because how well Cometriq works will ultimately determine how well the drug competes against Johnson & Johnson's (NYSE: JNJ  ) Zytiga and Medivation  (NASDAQ: MDVN  ) and Astellas' Xtandi.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss what the news means for Exelixis, Johnson & Johnson, Medivation, and Astellas.

Prostate cancer has nothing on this $14.4 trillion revolution
Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 trillion industry. Click here to get the full story in this eye-opening report.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2897721, ~/Articles/ArticleHandler.aspx, 10/24/2014 12:14:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement